Prostate Cancer - KOL Insight

What clinical factors underpin KOLs' opinions that use of Bayer's Nubeqa will increase? How do experts assess the prospects of Bayer's Xofigo in the face of competition from Novartis' Pluvicto? Do KOLs believe there is opportunity in PC for PD-1/PD-L1 therapies such as Roche's Tecentriq, Merck & Co's Keytruda and Bristol Myers Squibb's Opdivo? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (7)

Treatment algorithm

Research objectives (5)

Next-generation hormonal therapies (26)

• Marketed therapies (26)
  • Xtandi (enzalutamide; Astellas/Pfizer) (10)
  • Erleada (apalutamide; Janssen) (9)
  • Nubeqa (darolutamide; Bayer) (7)

Novel androgen-deprivation therapies (4)

• Marketed therapies (4)
  • Orgovyx (relugolix; Myovant Sciences/Pfizer) (4)

PARP inhibitors (29)

• Marketed therapies (23)
  • Rubraca (rucaparib; pharma&) (7)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (8)
  • Talzenna (talazoparib; Pfizer) (8)
• Pipeline therapies (6)
  • Zejula (niraparib; GSK) (6)

PD-1/PD-L1 checkpoint inhibitors (12)

• Pipeline therapies (12)
  • Tecentriq (atezolizumab; Roche), Opdivo (nivolumab; Bristol Myers Squibb) and Keytruda (pembrolizumab; Merck & Co.) (12)

Radiation-based therapies (25)

• Marketed therapies (25)
  • Xofigo (radium-223 dichloride; Bayer) (18)
  • Pluvicto (lutetium-177 vipivotide tetraxetan; Novartis) (7)

AKT inhibitors (5)

• Pipeline therapies (5)
  • Capivasertib (AstraZeneca) (5)

Cyclin-dependent kinase inhibitors (5)

• Pipeline therapies (5)
  • Verzenio (abemaciclib; Lilly) (5)

Combination therapies (5)

• Marketed therapies (5)
  • Akeega (niraparib + abiraterone acetate; Janssen) (5)

Antibody-dependent cell cytotoxicity agents (5)

• Pipeline therapies (5)
  • Enoblituzumab (MacroGenics) (5)

Future treatment paradigm (7)

• Key insights summary (7)

Appendix (3)

• KOL details (3)
  • KOLs from North America (1)
  • KOLs from Europe (1)